Company profile for Knopp Biosciences LLC

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The mission of Knopp Biosciences is to discover, develop, and deliver breakthrough medicines for devastating diseases and to improve global access to health care. We target diseases imposing high costs on the healthcare system, with patient populations clearly identifiable using validated biomarkers or genetic testing. Knopp is also committed to expanding the drug discovery and development industry in Western Pennsylvania. The...
The mission of Knopp Biosciences is to discover, develop, and deliver breakthrough medicines for devastating diseases and to improve global access to health care. We target diseases imposing high costs on the healthcare system, with patient populations clearly identifiable using validated biomarkers or genetic testing. Knopp is also committed to expanding the drug discovery and development industry in Western Pennsylvania. The Pittsburgh area is home to some of the nation's most significant and well-funded research institutions, creating a favorable environment for the biopharma industry.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2100 Wharton Street Suite 615 Pittsburgh, PA 15203
Telephone
Telephone
412-488-1776
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Bain leads $350M bet on oral asthma startup to fund phase 3
Bain leads $350M bet on oral asthma startup to fund phase 3

12 Jul 2022

// Nick Paul Taylor FIERCEBIOTECH

https://www.fiercebiotech.com/biotech/bain-goes-big-again-leading-350m-round-fund-oral-challenger-blockbuster-asthma-biologics

Nick Paul Taylor FIERCEBIOTECH
12 Jul 2022

https://www.businesswire.com/news/home/20220228005167/en

BUSINESSWIRE
28 Feb 2022

https://www.businesswire.com/news/home/20211020006172/de

BUSINESSWIRE
20 Oct 2021

https://www.businesswire.com/news/home/20210114005054/en/Knopp-Biosciences-Announces-Positive-Top-Line-Results-from-the-Phase-2-EXHALE-Trial-of-Oral-Dexpramipexole-in-Moderate-to-Severe-Eosinophilic-Asthma

BUSINESSWIRE
08 Sep 2021

https://www.businesswire.com/news/home/20210907005172/en

BUSINESSWIRE
07 Sep 2021

https://www.businesswire.com/news/home/20210907005477/nl

BUSINESSWIRE
07 Sep 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty